| scholarly article | Q13442814 |
| P2093 | author name string | Andrew H Talal | |
| Gene D Morse | |||
| Robin DiFrancesco | |||
| Andrew J Ocque | |||
| Colleen E Hagler | |||
| P2860 | cites work | ??? | Q27023574 |
| Direct anti-HCV agents | Q26767329 | ||
| Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies | Q36445132 | ||
| Gene expression analysis in serial liver fine needle aspirates | Q36487934 | ||
| Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers | Q36806650 | ||
| Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver | Q37046055 | ||
| Fine needle aspiration in the diagnosis of liver neoplasms: a review | Q37685722 | ||
| Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy | Q38703524 | ||
| Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice | Q38864101 | ||
| Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans | Q40674767 | ||
| A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma | Q40692889 | ||
| Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine | Q41358146 | ||
| Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial | Q41839327 | ||
| Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. | Q47636202 | ||
| P921 | main subject | liquid chromatography-tandem mass spectrometry | Q117788892 |
| P304 | page(s) | 103-109 | |
| P577 | publication date | 2017-03-24 | |
| P1433 | published in | Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences | Q2422407 |
| P1476 | title | Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates | |
| P478 | volume | 1052 |
| Q89900827 | Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats |
| Q64100619 | Development and validation of eco-friendly micellar-HPLC and HPTLC-densitometry methods for the simultaneous determination of paritaprevir, ritonavir and ombitasvir in pharmaceutical dosage forms |
| Q47567111 | Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage |
Search more.